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Abstract
Background: Neoadjuvant chemotherapy in breast cancer reduced mastectomy rates by 7% to 13% in randomized trials.
However, the differential effects for women with different stages, receptor subtypes, and ages are unknown. We compared
mastectomy rates in women who did vs did not receive neoadjuvant chemotherapy in 18 patient subgroups. The main
objective was to quantify the potential benefit from neoadjuvant chemotherapy in reducing mastectomy rates for each
subgroup.
Methods: Our retrospective analysis used data from the National Cancer Data Base, which includes approximately 70% of
incident cancers across the United States. Absolute risk reductions for mastectomy were determined for 18 subgroups of
clinical stage, receptor subtype, and age group. In each subgroup, propensity score weighting balanced measured covariates
between women treated with vs without neoadjuvant chemotherapy.
Results: A total of 55 709 patients were analyzed. In clinical stage IIA disease, only patients with human epidermal growth
factor receptor 2 (HER2)–positive tumors had reduced mastectomy rates associated with neoadjuvant chemotherapy (age <
60 years, 12%; age  60 years, 12.6%). For stage IIB cancers, neoadjuvant chemotherapy was associated with an absolute
reduction in mastectomy rates of 5.9% in women younger than age 60 years with hormone receptor–positive/HER2- disease,
8.2% to 10.7% for triple-negative disease, and 11.7% to 17.4% for HER2þ disease. For stage IIIA, the reductions in mastectomy
rates ranged from 6.6% to 15.9%.
Conclusions: In an analysis of patients treated across the United States, we found that neoadjuvant chemotherapy was
associated with a reduction in mastectomy rates to a similar magnitude overall as shown in randomized trials, but this
benefit varied widely by patient subgroup. This study provides novel information to help women make informed decisions
regarding treatment.
One important potential benefit of neoadjuvant chemotherapy
for women with early-stage breast cancers is to downsize the
tumor to better allow breast conservation (1–3). Long-term
results of the National Surgical Adjuvant Breast and Bowel
Project (NSABP) B-18 and the European Organization for the
Research and Treatment of Cancer (EORTC) 10902 trials showed
that neoadjuvant vs adjuvant chemotherapy was associated
with absolute risk reductions for mastectomy of 7% and 13%, re-
spectively (1,2). Based on these results, the National
Comprehensive Cancer Network (NCCN) guidelines recommend
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consideration of neoadjuvant therapy for women with clinical
stage IIA–IIIA cancers who desire breast conservation but are in-
eligible due to tumor size (4).
The benefit in terms of absolute reduction in mastectomy
rates from neoadjuvant chemotherapy likely differs by tumor
stage, receptor type, and patient age. For example, the ability of
neoadjuvant chemotherapy to reduce a need for mastectomy is
likely larger for a woman with stage IIIA, human epidermal
growth factor receptor 2 (HER2)–positive breast cancer com-
pared with one with stage IIA, hormone receptor (HR)–positive
disease. When a woman is deciding whether to receive neoadju-
vant chemotherapy, knowing the relative magnitude of benefit
based on her specific stage, receptor subtype, and age can help
with making an informed decision. However, these data do not
exist, and the aforementioned randomized trials report reduc-
tions in the rates of mastectomy for the overall group but not
the more specific rates in patient subgroups. It is also unlikely
that there will be future randomized trials specifically compar-
ing neoadjuvant vs adjuvant chemotherapy for each patient
stage, receptor subtype, and age subgroup to answer this
question.
Therefore, to address this clinically relevant knowledge gap,
we undertook this study using the National Cancer Data Base
(NCDB) to compare mastectomy rates in women who received
vs did not receive neoadjuvant chemotherapy, stratified by clin-
ical stage, tumor receptor subtype, and patient age. The NCDB
includes approximately 70% of all incident cancers across the
United States with patients, patient care, and outcomes broadly
representative of breast cancer patients in this country.
Methods
Data Source
The NCDB is administered jointly by the American College of
Surgeons’ Commission on Cancer (CoC) and the American
Cancer Society (5). All CoC-accredited institutions report data
using standardized coding definitions as detailed by the CoC’s
Facility Oncology Registry Data Standards. The NCDB contains
data on patient demographics, facility characteristics, county-
level socioeconomic characteristics, cancer diagnosis and tumor
characteristics, and first course of treatment. The type of pri-
mary breast cancer surgery is classified in the NCDB based on
standardized Surveillance, Epidemiology and End Results (SEER)
site-specific surgery primary site codes (6).
Patient Cohort
In this study, we searched the NCDB for women with incident
breast cancers diagnosed from 2010 to 2012 (Figure 1). This
study focused on women with clinical stage IIA (T2N0 only), IIB,
and IIIA (T3N1 only) disease because these are the specific
stages that the NCCN guidelines consider eligible for neoadju-
vant chemotherapy if a patient desires breast conservation but
is not eligible due to tumor size (4). Women with prior cancer di-
agnoses or missing data for stage, receipt of systemic therapy,
or primary surgery were excluded. Women who received neoad-
juvant endocrine therapy alone were also excluded (1% of
patients) so that this analysis could focus on the comparison of
patients who did vs did not receive neoadjuvant chemotherapy.
The study sample was limited to women with common histolo-
gies for breast cancer (International Classification of Diseases
for Oncology [3rd edition] histology codes 8500-8508 and 8520-
8524). This resulted in an analytic sample of 55 709 patients
(Figure 1).
Ascertainment of Neoadjuvant Chemotherapy
The NCDB contains data on the time from diagnosis to initiation
of chemotherapy and surgery. We classified patients as having
received neoadjuvant chemotherapy if their time from diagno-
sis to initiation of chemotherapy was less than the time from
diagnosis to surgery.
Ascertainment of Surgery Type
Type of surgery was ascertained based on standardized SEER
codes for breast cancer–specific surgery. Codes classified as
breast conserving surgery were 20–24. Codes classified as mas-
tectomy were 30, 40–74, and 80. Patients who underwent local
tumor destruction only (code 19), underwent a surgery of un-
known type (codes 90 and 99), or who did not have surgery
(code 0) were not included in the final data set.
Ascertainment of Covariates
Potential confounders collected by the NCDB and measured be-
fore or at the time of neoadjuvant therapy include tumor recep-
tor subtype, clinical American Joint Committee on Cancer stage,
tumor grade from biopsy, year of diagnosis, age, race, medical
insurance status, zip code education, zip code median income,
Charlson/Deyo Comorbidity Score, rurality, facility type, and fa-
cility location.
Statistical Analysis
The overall goal of this study was to compare the mastectomy





114 753 No prior cancer diagnosis 527 973
24 136 At least part of treatment or decision-
making performed at reporting facility
503 837
4627 Females only 499 210
44 804 Histology ductal, lobular, mixed ductal
and lobular 
454 406
366 500 Include only clinical stage IIA (T2N0), 
IIB, IIIA (T3N1)
87 906
3790 Patients must have undergone surgery 84 116
14 270 Receipt of systemic 
therapy/surgery sequence is known, and exclude 
neoadjuvant endocrine-only treatment.
69 846
14 137 Complete data for covariates 55 709
Figure 1. Selection of cases and exclusion (flow diagram).
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chemotherapy and to conduct this analysis separately for each
patient subgroup based on stage, receptor subtype, and age. Age
60 years was chosen for stratification because it is a clinically
sensible boundary between older and younger patients, and it is
also close to the national median age of breast cancer diagnosis.
To balance measured confounders in each subgroup among
women who received vs did not receive neoadjuvant chemo-
therapy, we constructed separate propensity score (PS) models
using multivariable logistic regression to estimate the probabil-
ity that each patient received neoadjuvant chemotherapy. This
resulted in 18 PS models (all combinations for three stage
groups, three receptor subgroups, and two age groups). These
models included known confounders and predictors of mastec-
tomy receipt, including all variables in Table 1. To control for
measured confounders, we balanced the covariates across treat-
ment groups using standardized mortality ratio (SMR) weight-
ing, assigning a weight of 1 for patients treated with
neoadjuvant chemotherapy and a weight of the propensity
odds [(PS)/(1-PS)] for patients who did not receive neoadjuvant
chemotherapy, creating a “pseudo-population” of patients who
did not receive neoadjuvant chemotherapy with the same co-
variate distribution as that observed in patients who received
neoadjuvant chemotherapy (7,8). Covariate balance was evalu-
ated using standardized absolute mean difference (SAMD); ade-
quate balance was considered at an SAMD of less than 0.1
(Supplementary Tables 1–18) (9). Due to small sample sizes in
the stage IIIA subgroups, only race, insurance, and facility type
were included in the PS models. This resulted in residual con-
founding for some variables across treatment groups, and bino-
mial regression was then used to control for the few variables
that were still unbalanced (Supplementary Tables 5, 6, 11, 12,
17, and 18, available online). Crude and weighted proportions of
patients undergoing mastectomy were reported for women who
received vs did not receive neoadjuvant chemotherapy in each
patient subgroup. SMR-weighted risk differences and relative
risks for mastectomy with vs without neoadjuvant chemother-
apy and 95% confidence intervals were estimated using bino-
mial regression models with a robust variance.
Statistical analyses were performed with SAS software ver-
sion 9.4 (SAS Institute Inc., Cary, NC), and a two-sided P value of
less than .05 was considered statistically significant.
Results
Table 1 describes the baseline characteristics of the 55 709
patients included for analysis. Patients excluded due to missing







Total 41 326 14 383
Age, y
<40 2883 (7) 2296 (16)
40–49 8.426 (20) 4249 (30)
50–59 10 928 (26) 4462 (31)
60–69 10 439 (25) 2549 (18)
70–79 5841 (14) 717 (5)
80 2809 (7) 110 (1)
Race
White non-Hispanic 31 771 (77) 9855 (69)
Black non-Hispanic 5226 (13) 2582 (18)
Hispanic 2496 (6) 1213 (8)
Other 1833 (4) 733 (5)
Insurance status
Private 23 335 (57) 9742 (68)
Medicaid 3571 (9) 1867 (13)
Medicare 12 845 (31) 1976 (14)
None or other government 1575 (4) 798 (6)
Zip code median income
<$30 000 4859 (12) 1699 (12)
$30 000–$35 999 6914 (17) 2230 (16)
$36 000–$45 999 11 380 (28) 3912 (27)
$46 000 18 173 (44) 6542 (46)
Percent of zip code area without a high school degree
29% 6446 (16) 2384 (17)
20%–28.9% 9080 (22) 3085 (21)
14%–19.9% 9510 (23) 3214 (22)
<14% 16 290 (39) 5700 (40)
Year of diagnosis
2010 13 534 (33) 4297 (30)
2011 14 285 (35) 4997 (35)
2012 13 507 (33) 5089 (35)
Charlson/Deyo comorbidity score
0 33 980 (82) 12 758 (89)
1 6032 (15) 1400 (10)
2þ 1314 (3) 225 (2)
Facility location
South 15 696 (38) 5866 (41)
Midwest 11 035 (27) 3561 (25)
Northeast 7584 (18) 2484 (17)
West 7011 (17) 2472 (17)
Facility type
Academic/research 12 296 (30) 5345 (37)
Comprehensive community
cancer program
24 380 (59) 7918 (55)
Community cancer program 4650 (11) 1120 (8)
Population density
Nonrural 40 551 (98) 14 187 (99)
Rural 775 (2) 196 (1)
Grade
1 4693 (11) 768 (5)
2 17 454 (42) 4865 (34)
3 19 179 (46) 8750 (61)
ER/PR/HER2 summary
ERþ or PRþ/HER2- 28 599 (69) 6282 (44)
ERþ or PRþ/HER2þ 4442 (11) 2475 (17)
ER-/PR-/HER2þ 2002 (5) 1498 (10)
ER-/PR-/HER2- 6283 (15) 4128 (29)
AJCC clinical stage









IIB 9406 (23) 6650 (46)
IIIA (only T3 N1) 1260 (3) 2795 (19)
Histology
Invasive ductal carcinoma 33 690 (82) 13 002 (90)
Invasive lobular carcinoma 5108 (12) 869 (6)
Mixed ductal and lobular 2528 (6) 512 (4)
Laterality
Unilateral 41 319 (>99) 14 382 (>99)
Bilateral 7 (<1) 1 (<1)
*AJCC ¼ American Joint Committee on Cancer; ER ¼ estrogen receptor; PR ¼
progesterone receptor; HER2 ¼ human epidermal growth factor receptor-2.
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data had baseline characteristics similar to the final analysis
sample (Supplementary Table 1), except that excluded patients
were older and more had Medicare insurance. Overall, 69% to
77% of women were Caucasian and 67% to 70% were treated in
community cancer centers. The numbers of patients with stage
IIA, IIB, and IIIA cancers were 35 598 (64%), 16 056 (29%), and 4055
(7%), respectively. After propensity score adjustment, patient
characteristics among those who received vs did not receive neo-
adjuvant chemotherapy were not different in any patient sub-
group among patients with stage IIA or IIB disease (details are
shown in Supplementary Tables 2–5, 8–11, and 14–17, available
online). Due to smaller sample sizes, subgroups of patients with
stage IIIA disease had some remaining imbalances in covariates
after propensity score weighting (details are shown in
Supplementary Tables 6, 7, 12, 13, 18, and 19, available online);
this was further accounted for using multivariable modeling.
Mastectomy rates were calculated separately among women
who received vs did not receive neoadjuvant chemotherapy in
each of the 18 subgroups (3 stages  3 receptor subtypes  2 age
subgroups). These results are summarized in Table 2. Both
crude and propensity score–weighted rates were reported, and
they differed minimally (<3% absolute change in results after
propensity adjustment for all groups), suggesting that stratifica-
tion controlled much of the measured confounding for the asso-
ciation between neoadjuvant chemotherapy and mastectomy
(Table 2).
Among patients with clinical stage IIA disease, only patients
with HER2-positive tumors appeared to benefit from neoadju-
vant chemotherapy in reducing mastectomy rates (age <
60 years, mastectomy 47.5% vs 59.5% without neoadjuvant che-
motherapy, P < .001; age  60 years, 39.2% vs 51.8%, P ¼ .001).
For visual presentation, the absolute reduction in mastectomy
Table 2. Proportion of patients who underwent mastectomy by neoadjuvant chemotherapy receipt before and after propensity score weighing,












<60 778/1461 (53.3)† 5798/10,532 (55.1) 53.3 55.5 .23
60 240/485 (49.5) 5399/11,053 (48.8) 49.5 47.5 .53
HER2þ
<60 456/959 (47.5) 1502/2575 (58.3) 47.5 59.5 <.001
60 130/332 (39.2) 983/1840 (53.4) 39.2 51.8 .001
Triple-negative
<60 616/1319 (46.7) 1437/3021 (47.6) 46.7 49.2 .20
60 136/382 (35.6) 697/1639 (42.5) 35.6 41.5 .09
Stage IIB
HRþ/HER2-
<60 1534/2239 (68.5) 2465/3303 (74.6) 68.5 74.4 <.001
60 490/777 (63.1) 1966/2885 (68.1) 63.1 65.6 .29
HER2þ
<60 896/1454 (61.6) 795/1102 (72.1) 61.6 73.3 <.001
60 234/427 (54.8) 484/667 (72.6) 54.8 72.2 <.001
Triple-negative
<60 806/1374 (58.7) 621/935 (66.4) 58.7 66.8 <.001
60 193/379 (50.9) 323/514 (62.8) 50.9 61.6 .003
Stage IIIA
HRþ/HER2-
<60 864/1020 (84.7) 451/487 (92.6) 84.7 92.6 <.001 (not controlled)
<.001 (controlled)‡
60 258/300 (86.0) 311/339 (91.7) 86.0 90.9 .06 (not controlled)
.43 (controlled)‡
HER2þ
<60 536/643 (83.4) 150/164 (91.5) 83.4 91.4 <.001 (not controlled)
<.001 (controlled)‡
60 116/158 (73.4) 83/96 (86.5) 73.4 86.7 .003 (not controlled)
.04 (controlled)‡
Triple-negative
<60 414/538 (77.0) 101/118 (85.6) 77.0 87.1 <.001 (not controlled)
<.001 (controlled)‡
60 99/136 (72.8) 49/56 (87.5) 72.8 88.7 <.001 (not controlled)
.006 (controlled)‡
*By convention, the group treated with neoadjuvant chemotherapy has propensity weight of 1. covs ¼ covariates; ER ¼ estrogen receptor; HER2 ¼ human epidermal
growth factor receptor 2; IHC ¼ immunohistochemistry; PR ¼ progesterone receptor.
‡Due to small sample sizes, only race, insurance, and facility type were included in the propensity score models for stage 3A. Binomial regression was then used to
control for the few variables that were still unbalanced.
†Ratios represent the number of women who had mastectomy divided by all patients in the specific subgroup.
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rates among women who received vs did not receive neoadju-
vant chemotherapy, with 95% confidence intervals, is presented
in Figure 2. Therefore, for clinical stage IIA and HER2-positive
breast cancer, neoadjuvant chemotherapy was associated with
an absolute reduction in mastectomy of 12.0% for women youn-
ger than age 60 years and 12.6% for women age 60 years or older.
For women with clinical stage IIB and IIIA breast cancers,
neoadjuvant chemotherapy was associated with decreased
mastectomy rates in almost all patient subgroups, but the mag-
nitude of effect differed dramatically (Table 2 and Figure 2).
Patients with HER2-positive or triple-negative cancers appeared
to have greater magnitudes of benefit from neoadjuvant chemo-
therapy than patients with HRþ/HER2- disease. More specifi-
cally, for patients with clinical stage IIB cancers, neoadjuvant
chemotherapy was associated with a reduction in mastectomy
rates of 5.9% in younger women with HRþ/HER2- disease, 8.2%
to 10.7% in women with with triple-negative disease, and 11.7%
to 17.4% in women with HER2-positive disease. For clinical stage
IIIA cancers, the reductions in mastectomy rates were 6.6%
(HRþ/HER2- age < 60 years), 10.6% to 15.9% (triple-negative), and
8.0% to 10.6% (HER2-positive), respectively.
Discussion
For women with early-stage breast cancers, randomized trial
data showed that neoadjuvant chemotherapy was associated
with a 7% to 13% absolute reduction in mastectomy rates
among all women enrolled in the trials (included stage T1c-T4b
N0-1 and all ages and receptor subtypes) (1,2). These trials were
not large enough to perform subgroup analyses to better assess
the magnitude of benefit by patient stage, receptor subtype, and
age. Therefore, we undertook this analysis using a large and
representative cancer registry of patients from across the
United States to fill this current knowledge gap. Specifically, we
compared the mastectomy rates of patients who received vs did
not receive neoadjuvant chemotherapy in 18 subgroups based
on stage, receptor subtype, and patient age.
While the ideal study design to assess the potential benefit
of neoadjuvant chemotherapy would be randomized trials, it is
unlikely that randomized trials will be performed separately to
answer this question for each of the 18 patient subgroups to as-
sess the magnitude of benefit in each based on patient charac-
teristics. Lacking randomized trial data, we used the best
alternative approach—utilizing data from a large cancer registry
to analyze more than 55 000 contemporary (2010–2012)
patients—but we acknowledge that there are important poten-
tial limitations with this approach. Most notably, there can be
imbalances between the comparison groups including disease
characteristics and patient and physician preferences regarding
breast conservation, as well as unknown information in the
NCDB including chemotherapy type and duration. Additionally,
it is unknown what proportion of patients initially attempted
breast conservation but required a mastectomy due to positive
or close margins. We utilized sophisticated analytic methods
for observational data including stratification and propensity
score weighting to minimize confounding of measured charac-
teristics, but we recognize that residual confounding, especially
in unmeasured variables, is possible. This study is an example
of utilizing big data to learn from more patients than those en-
rolled in clinical trials. Were a randomized trial to be performed,
the population of patients with HRþ/HER2- could be further
studied; based on our results, the benefit of neoadjuvant
chemotherapy for reducing mastectomy rates in this subgroup
is most uncertain.
Despite these potential limitations, our results have face va-
lidity. The observed reductions in the rates of mastectomy asso-
ciated with neoadjuvant chemotherapy were consistent with
those reported from the prospective randomized trials NSABP
B-18 (7%) and EORTC 10902 (13%). In addition, the demonstrated
differences in rates of mastectomy reduction by different pa-
tient subgroups are consistent with known differences in tumor
sensitivity to chemotherapy. Specifically, we found that neoad-
juvant chemotherapy was not associated with lower mastec-
tomy rates in several patient groups: stage IIA HRþ/HER2-, stage
IIA triple-negative, stage IIB HRþ/HER2- age 60 years or older,
and stage IIIA HRþ/HER2- age 60 years or older. The reduced
benefit of neoadjuvant chemotherapy for patients with HRþ/
























































































Figure 2. Propensity score weighted absolute risk reduction of mastectomy with
95% confidence intervals by receptor subtype and age group for (A) stage IIA
(T2N0 only), (B) stage IIB, and (C) stage IIIA (T3N1 only). Risk reductions calcu-
lated as the difference between mastectomy rates for each subgroup of patients
treated with vs without neoadjuvant chemotherapy. Note that a reduction in
mastectomy rate is represented as a positive number. HER2 ¼ human epidermal
growth factor receptor 2; HR ¼ hormone receptor; TN ¼ triple-negative.
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phase II trial ACOSOG Z1071, which showed that the HRþ/HER2-
subtype is associated with relatively low rates of pathologic
complete response and breast conservation (10). For the other
patient subgroups, neoadjuvant chemotherapy was associated
with absolute reductions in mastectomy rates ranging between
5.9% and 17.4%. While physicians have known that different
types of breast cancers respond differently to chemotherapy, to
our knowledge, this study is the first to provide numbers to as-
sociate this knowledge with mastectomy rates with vs without
neoadjuvant chemotherapy.
0.6 0.8 1 1.2 1.4
Relative risk
IIA, age < 60, HR+/HER2-
IIA, age < 60, HER2+
IIA, age < 60, triple-negative
IIA, age ≥ 60, HR+/HER2-
IIA, age ≥ 60, HER2+
IIA, age ≥ 60, triple-negative
0.6 0.8 1 1.2 1.4
Relative risk
IIB, age < 60, HR+/HER2-
IIB, age < 60, HER2+
IIB, age < 60, triple-negative
IIB, age ≥ 60, HR+/HER2-
IIB, age ≥ 60, HER2+
IIB, age ≥ 60, triple-negative
0.6 0.8 1 1.2 1.4
Relative risk
IIIA, age < 60, HR+/HER2-
IIIA, age < 60, HER2+
IIIA, age < 60, triple-negative
IIIA, age ≥ 60, HR+/HER2-
IIIA, age ≥ 60, HER2+
IIIA, age ≥ 60, triple-negative
Figure 3. Propensity score weighted relative risk reduction of mastectomy with 95% confidence intervals by receptor subtype and age group for (A) stage IIA (T2N0
only), (B) stage IIB, and (C) stage IIIA (T3N1 only). Relative risks are calculated from rates of mastectomy in patients treated with vs without neoadjuvant chemotherapy
in each subgroup. Relative risk of less than 1 means that neoadjuvant chemotherapy was associated with a reduced mastectomy rate. HER2 ¼ human epidermal
growth factor receptor 2; HR ¼ hormone receptor.
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We recognize that there may be other benefits to neoadju-
vant chemotherapy that can contribute to a patient’s decision.
Neoadjuvant chemotherapy has not been shown to improve
overall survival compared with adjuvant chemotherapy (1,2),
but giving chemotherapy prior to surgery may allow in vivo as-
sessment of tumor response to systemic therapy. From a
patient’s perspective, though, knowing the potential reduction
in the mastectomy rate is likely one of the most important fac-
tors in this decision.
Results from this study may represent conservative esti-
mates of the potential benefit from neoadjuvant chemotherapy
in reducing mastectomy rates. We suspect that women who
were able to have breast conserving surgeries without neoadju-
vant treatment would likely have received surgery right away,
while women who clinically may have needed neoadjuvant
chemotherapy in order to have breast conserving surgery would
be more likely to be in the neoadjuvant chemotherapy group.
Thus, even though our analysis was stratified by clinical stage,
women in the neoadjuvant chemotherapy group may have had
larger tumors than women who did not receive neoadjuvant
chemotherapy within each stage subgroup. If true, this would
bias the results in terms of mastectomy rates against the neoad-
juvant chemotherapy group, thus making our results conserva-
tive estimates of treatment benefit.
There are several important strengths of this study. The
large sample size of the NCDB allowed for detailed analyses to
be performed for 18 different patient subgroups. There are no
other prospective or retrospective data to inform patients on
the relative effectiveness of neoadjuvant chemotherapy based
on patients’ age group, tumor receptor subtype, and stage.
These variables are important predictors of body image con-
cerns, chemosensitivity, and breast conservation eligibility, re-
spectively (4,10,11); they may modify the mastectomy risk
reduction of neoadjuvant chemotherapy. Additionally, the pa-
tient cohort used in this study reflects more than 1400 cancer
centers across the United States and allows these results to be
more generalizable than those from clinical trials that often se-
lect for younger and healthier patients (12).
The absolute reduction in mastectomy rates associated with
the use of neoadjuvant chemotherapy varied widely among
patients based on clinical stage, receptor subtype, and age.
Overall, we found that mastectomy reduction associated with
neoadjuvant chemotherapy was greatest among patients with
HER2-positive disease, and also with most subgroups of patients
with triple-negative disease. In contrast, older patients with HRþ/
HER2- disease had less benefit comparatively. These data fill a
knowledge gap and provide currently unavailable information
that physicians can share with their patients when individualizing
neoadjuvant treatment decisions. Because increasing the proba-
bility of breast conservation is one important consideration in the
decision-making process regarding neoadjuvant chemotherapy
for early breast cancer, the data provided in this study can further
help patients make an informed decision.
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